Five Prime Lands Blow On Gastric Cancers With FGFR2b Antibody

Positive Top-Line Data From Phase II FIGHT Trial

11 Nov 2020

• By John Davis

A potential first-in-class FGFR2b-targeted monoclonal antibody, bemarituzumab, has shown top-line benefits in the Phase II FIGHT study in advanced gastric or gastroesophageal junction cancers.

gray slate stone rock wall with breakthrough hole breakout freedom concept in front of green meadow with blue sky background - Image — Bemarituzumab could be a breakthrough in certain gastric cancers • Source: Shutterstock

Investors have reacted positively to top-line Phase II data released by the South San Francisco-based biotech Five Prime Therapeutics, Inc., which suggested the potential first-in-class MAb, bemarituzumab, could be the first targeted therapy for HER2-negative advanced gastric cancer in more than a decade.

The share price of the NASDAQ-quoted US biotech rose from $5.34 to $24

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

China Biopharma Podcast - 14 May 2025 (Chinese Language)

14 May 2025

• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

13 May 2025

• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

13 May 2025

• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.